Antibacterial agent triclosan suppresses RBL-2H3 mast cell function

Toxicology and Applied Pharmacology

Volumn 258, Issue 1, 2012, Pages 99-108

  Palmer, Rachel K ^a   Hutchinson, Lee M ^a   Burpee, Benjamin T ^a   Tupper, Emily J ^a   Pelletier, Jonathan H ^a   Kormendy, Zsolt ^a   Hopke, Alex R ^a   Malay, Ethan T ^a   Evans, Brieana L ^a   Velez, Alejandro ^a   Gosse, Julie A ^a  

^a UNIVERSITY OF MAINE   (United States)

Author keywords

Basophils; Degranulation; Irgasan; Mast cells; RBL 2H3; Triclosan

Indexed keywords

CALCIUM IONOPHORE; F ACTIN; IMMUNOGLOBULIN E RECEPTOR; TRICLOSAN; TYROSINE;

ANIMAL CELL; ARTICLE; CELL ASSAY; DRUG MECHANISM; FLUORESCENT MICROPLATE ASSAY; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; CALCIUM IONOPHORES; CELL DEGRANULATION; CELL LINE, TUMOR; MAST CELLS; RATS; RECEPTORS, IGE; TRICLOSAN;

RATTUS;

EID: 84855421528     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.10.012     Document Type: Article

References (64)

1. Ahn K.C., Zhao B., Chen J., Cherednichenko G., Sanmarti E., Denison M.S., Lasley B., Pessah I.N., Kultz D., Chang D.P.Y., Gee S.J., Hammock B.D. In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screens. Environ. Heal. Perspect. 2008, 116:1203-1210.
2. Allmyr M., Harden F., Toms L.M.L., Mueller J.F., McLachlan M.S., Adolfsson-Erici M., Sandborgh-Englund G. The influence of age and gender on triclosan concentrations in Australian human blood serum. Sci. Total. Environ. 2008, 393:162-167.
3. Anto J.M., Sunyer J., Basagana X., Garcia-Esteban R., Cerveri I., de Marco R., Heinrich J., Janson C., Jarvis D., Kogevinas M., Kuenzli N., Leynaert B., Svanes C., Wjst M., Gislason T., Burney P. Risk factors of new-onset asthma in adults: a population-based international cohort study. Allergy 2010, 65:1021-1030.
4. Bagley D.M., Lin Y.J. Clinical evidence for the lack of triclosan accumulation from daily use in dentifrices. Am. J. Dent. 2000, 13:148-152.
5. Barkvoll P., Rolla G. Triclosan protects the skin against dermatitis caused by sodium lauryl sulfate exposure. J. Dent. Res. 1995, 74:476-476.
6. Barkvoll P., Rolla G. Triclosan reduces the clinical symptoms of the allergic patch test reaction (APR) elicited with 1-percent nickel sulfate in sensitized patients. J. Clin. Periodontol. 1995, 22:485-487.
7. Barros S.P., Wirojchanasak S., Barrow D.A., Panagakos F.S., DeVizio W., Offenbacher S. Triclosan inhibition of acute and chronic inflammatory gene pathways. J. Clin. Periodontol. 2010, 37:412-418.
8. Barsumian E.L., Isersky C., Petrino M.G., Siraganian R.P. IgE-induced histamine-release from rat basophilic leukemia-cell lines - isolation of releasing and non-releasing clones. Eur. J. Immunol. 1981, 11:317-323.
9. Beaven M.A., Metzger H. Signal-transduction by Fc-receptors - the Fc-epsilon-RI case. Immunol. Today 1993, 14:222-226.
10. Benhamou M., Stephan V., Robbins K.C., Siraganian R.P. High-affinity IgE receptor-mediated stimulation of rat basophilic leukemia (RBL-2H3) cells induces early and late protein-tyrosine phosphorylations. J. Biol. Chem. 1992, 267:7310-7314.
11. Bhargava H.N., Leonard P.A. Triclosan: applications and safety. Am. J. Infect. Control. 1996, 24:209-218.
12. Black J.G., Howes D., Rutherford T. Percutaneous absorption and metabolism of Irgasan DP300. Toxicology 1975, 3:33-47.
13. Blank U., Cyprien B., Martin-Verdeaux S., Paumet F., Pombo I., Rivera J., Roa M., Varin-Blank N. SNAREs and associated regulators in the control of exocytosis in the RBL-2H3 mast cell line. Mol. Immunol. 2002, 38:1341-1345.
14. Blank U., Essig M., Scandiuzzi L., Benhamou M., Kanamaru Y. Mast cells and inflammatory kidney disease. Immunol. Rev. 2007, 217:79-95.
15. Boguniewicz M., Leung D.Y.M. Recent insights into atopic dermatitis and implications for management of infectious complications. J. Allergy Clin. Immunol. 2010, 125:4-13.
16. Breneman D.L., Hanifin J.M., Berge C.A., Keswick B.H., Neumann P.B. The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis 2000, 66:296-300.
17. Calafat A.M., Ye X., Wong L.Y., Reidy J.A., Needham L.L. Urinary concentrations of triclosan in the US population: 2003-2004. Environ. Heal. Perspect. 2008, 116:303-307.
18. Dvorak A.M. Mast-cell degranulation in human hearts. N. Engl. J. Med. 1986, 315:969-970.
19. Fang J.L., Stingley R.L., Beland F.A., Harrouk W., Lumpkins D.L., Howard P. Occurrence, efficacy, metabolism, and toxicity of triclosan. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2010, 28:147-171.
20. Farrell D.J., Hines J.E., Walls A.F., Kelly P.J., Bennett M.K., Burt A.D. Intrahepatic mast-cells in chronic liver-diseases. Hepatology 1995, 22:1175-1181.
21. Ferris C.D., Huganir R.L., Supattapone S., Snyder S.H. Purified inositol 1,4,5-triphosphate receptor mediates calcium flux in reconstituted lipid vesicles. Nature 1989, 342:87-89.
22. Fewtrell C., Kessler A., Metzger H. Comparative aspects of secretion from tumor and normal mast cells. Adv. Inflamm. Res 1979, 1:205-221.
23. Foran C.M., Bennett E.R., Benson W.H. Developmental evaluation of a potential non-steroidal estrogen: triclosan. Mar. Environ. Res. 2000, 50:153-156.
24. Gee R.H., Charles A., Taylor N., Darbre P.D. Oestrogenic and androgenic activity of triclosan in breast cancer cells. J. Appl. Toxicol. 2008, 28:78-91.
25. Helbing C.C., van Aggelen G., Veldhoen N. Triclosan affects thyroid hormone-dependent metamorphosis in anurans. Toxicol. Sci. 2011, 119:417-418.
26. Hutchinson L.M., Trinh B.M., Palmer R.K., Preziosi C.A., Pelletier J.H., Nelson H.M., Gosse J.A. Inorganic arsenite inhibits IgE receptor-mediated degranulation of mast cells. J. Appl. Toxicol. 2011, 31:231-241.
27. Ishibashi H., Matsumura N., Hirano M., Matsuoka M., Shiratsuchi H., Ishibashi Y., Takao Y., Arizono K. Effects of triclosan on the early life stages and reproduction of medaka Oryzias latipes and induction of hepatic vitellogenin. Aquat. Toxicol. 2004, 67:167-179.
28. Jappe U., Schnuch A., Uter W. Frequency of sensitization to antimicrobials in patients with atopic eczema compared with nonatopic individuals: analysis of multicentre surveillance data, 1995-1999. Br. J. Dermatol. 2003, 149:87-93.
29. Jensen-Jarolim E., Untersmayr E. Gender-medicine aspects in allergology. Allergy 2008, 63:610-615.
30. Jones R.D., Jampani H.B., Newman J.L., Lee A.S. Triclosan: a review of effectiveness and safety in health care settings. Am. J. Infect. Control. 2000, 28:184-196.
31. Kanetoshi A., Katsura E., Ogawa H., Ohyama T., Kaneshima H., Miura T. Acute toxicity, percutaneous-absorption and effects on hepatic mixed-function oxidase activities of 2,4,4'-trichloro-2'-hydroxydiphenyl ether (Irgasan(R) DP300) and its chlorinated derivatives. Arch. Environ. Contam. Toxicol. 1992, 23:91-98.
32. Kjaerheim V., Barkvoll P., Waaler S.M., Rolla G. Triclosan inhibits histamine-induced inflammation in human skin. J. Clin. Periodontol. 1995, 22:423-426.
33. Kuby J. Immunology 1997, W.H. Freeman, New York.
34. Kumar V., Chakraborty A., Kural M.R., Roy P. Alteration of testicular steroidogenesis and histopathology of reproductive system in male rats treated with triclosan. Reprod. Toxicol. 2009, 27:177-185.
35. Lee J.H., Haselkorn T., Chipps B.E., Miller D.P., Wenzel S.E., Grp T.S. Gender differences in IgE-mediated allergic asthma in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. J. Asthma 2006, 43:179-184.
36. Levy C.W., Roujeinikova A., Sedelnikova S., Baker P.J., Stuitje A.R., Slabas A.R., Rice D.W., Rafferty J.B. Molecular basis of triclosan activity. Nature 1999, 398:383-384.
37. Lin Y.J. Buccal absorption of triclosan following topical mouthrinse application. Am. J. Dent. 2000, 13:215-217.
38. Matsumura N., Ishibashi H., Hirano M., Nagao Y., Watanabe N., Shiratsuchi H., Kai T., Nishimura T., Kashiwagi A., Arizono K. Effects of nonylphenol and triclosan on production of plasma vitellogenin and testosterone in male South African clawed frogs (Xenopus laevis). Biol. Pharm. Bull. 2005, 28:1748-1751.
39. McHugh M.K., Symanski E., Pompeii L.A., Delclos G.L. Prevalence of asthma among adult females and males in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2001-2004. J. Asthma 2009, 46:759-766.
40. McMurry L.M., Oethinger M., Levy S.B. Triclosan targets lipid synthesis. Nature 1998, 394:531-532.
41. Melgert B.N., Ray A., Hylkema M.N., Timens W., Postma D.S. Are there reasons why adult asthma is more common in females?. Curr. Allergy Asthma Rep. 2007, 7:143-150.
42. Metzger H., Alcaraz G., Hohman R., Kinet J.P., Pribluda V., Quarto R. The receptor with high-affinity for immunoglobulin-E. Annu. Rev. Immunol. 1986, 4:419-470.
43. Millard P.J., Ryan T.A., Webb W.W., Fewtrell C. Immunoglobulin-E receptor cross-linking induces oscillations in intracellular free ionozed calcium in individual tumor mast-cells. J. Biol. Chem. 1989, 264:19730-19739.
44. Naal R., Tabb J., Holowka D., Baird B. In situ measurement of degranulation as a biosensor based on RBL-2H3 mast cells. Biosens. Bioelectron. 2004, 20:791-796.
45. Narita S., Goldblum R.M., Watson C.S., Brooks E.G., Estes D.M., Curran E.M., Midoro-Horiuti T. Environmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators. Environ. Heal. Perspect. 2007, 115:48-52.
46. Ortega E., Lara A., Lee I., Santana C., Martinez A.M., Pfeiffer J.R., Lee R.J., Wilson B.S., Oliver J.M. Lyn dissociation from phosphorylated Fc epsilon RI subunits: a new regulatory step in the Fc epsilon RI signaling cascade revealed by studies of Fc epsilon RI dimer signaling activity. J. Immunol. 1999, 162:176-185.
47. Putney J.W. Capacitative calcium entry: from concept to molecules. Immunol. Rev. 2009, 231:10-22.
48. Putney J.W., Broad L.M., Braun F.J., Lievremont J.P., Bird G.S.J. Mechanisms of capacitative calcium entry. J. Cell Sci. 2001, 114:2223-2229.
49. Queckenberg C., Meins J., Wachall B., Doroshyenko O., Tomalik-Scharte D., Bastian B., Abdel-Tawab M., Fuhr U. Absorption, pharmacokinetics, and safety of triclosan after dermal administration. Antimicrob. Agents Chemother. 2010, 54:570-572.
50. Rodricks J.V., Swenberg J.A., Borzelleca J.F., Maronpot R.R., Shipp A.M. Triclosan: a critical review of the experimental data and development of margins of safety for consumer products. Crit. Rev. Toxicol. 2010, 40:422-484.
51. Russell A.D. Whither triclosan?. J. Antimicrob. Chemother. 2004, 53:693-695.
52. Sandborgh-Englund G., Adolfsson-Erici M., Odham G., Ekstrand J. Pharmacokinetics of triclosan following oral ingestion in humans. J. Toxicol. Environ. Health A Curr. Issues 2006, 69:1861-1873.
53. Schatz M., Clark S., Camargo C.A. Sex differences in the presentation and course of asthma hospitalizations. Chest 2006, 129:50-55.
54. Schena D., Papagrigoraki A., Girolomoni G. Sensitizing potential of triclosan and triclosan-based skin care products in patients with chronic eczema. Dermatol. Ther. 2008, 21:S35-S38.
55. Schwartz L.B., Austen K.F., Wasserman S.I. Immunological release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast-cells. J. Immunol. 1979, 123:1445-1450.
56. Seldin D.C., Adelman S., Austen K.F., Stevens R.L., Hein A., Caulfield J.P., Woodbury R.G. Homology of the rat basophilic leukemia-cell and the rat mucosal mast-cell. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:3871-3875.
57. Siraganian R.P., Kulczycki A., Mendoza G., Metzger H. Ionophore A-23187 induced histamine-release from mast-cells and rat basiphil leukemia (RBL-1) cells. J. Immunol. 1975, 115:1599-1602.
58. Sporik R., Kemp A.S. Topical triclosan treatment of atopic dermatitis. J. Allergy Clin. Immunol. 1997, 99:861-861.
59. Tan W.P., Suresh S., Tey H.L., Chiam L.Y., Goon A.T. A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis. Clin. Exp. Dermatol. 2010, 35:e109-e112.
60. Udoji F., Martin T., Etherton R., Whalen M.M. Immunosuppressive effects of triclosan, nonylphenol, and DDT on human natural killer cells in vitro. J. Immunotoxicol. 2010, 7:205-212.
61. Veldhoen N., Skirrow R.C., Osachoff H., Wigmore H., Clapson D.J., Gunderson M.P., Van Aggelen G., Helbing C.C. The bactericidal agent triclosan modulates thyroid hormone-associated gene expression and disrupts postembryonic anuran development. Aquat. Toxicol. 2006, 80:217-227.
62. Vink N.M., Postma D.S., Schouten J.P., Rosmalen J.G.M., Boezen H.M. Gender differences in asthma development and remission during transition through puberty: the TRacking Adolescents' Individual Lives Survey (TRAILS) study. J. Allergy Clin. Immunol. 2010, 126:498-U162.
63. Wohlrab J., Jost G., Abeck D. Antiseptic efficacy of a low-dosed topical triclosan/chlorhexidine combination therapy in atopic dermatitis. Ski. Pharmacol. Physiol. 2007, 20:71-76.
64. Zaitsu M., Narita S.I., Lambert K.C., Grady J.J., Estes D.M., Curran E.M., Brooks E.G., Watson C.S., Goldblum R.M., Midoro-Horiuti T. Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol. Immunol. 2007, 44:1977-1985.